5 Qs on the New Acute Ischemic Stroke Guidelines

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is National Epilepsy Awareness Month!

Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.

As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.

At a NeurologyLive Clinical Forum in Philadelphia, Chafic Karam, MD, chief of neuromuscular medicine at Penn Medicine, discussed treatment sequencing in myasthenia gravis.

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).